A Phase 2b Trial Testing Weekly Navepegritide Injections for Adolescents Aged 12 to 17 with Achondroplasia

What this Trial Is About

Researchers are evaluating the effectiveness and safety of once-weekly subcutaneous doses of navepegritide at 100 micrograms per kilogram compared to a placebo in adolescents aged 12 to 18 years with Achondroplasia. The main focus is to measure the annualized growth velocity after a 52-week treatment period. Participants will receive either navepegritide or a placebo through weekly injections under the skin for one year. The study is randomized, double-blinded, and placebo-controlled, ensuring that neither the participants nor the researchers know who receives the active medication or placebo during the 52 weeks. During the trial, participants will be monitored regularly to assess growth and other health parameters. Researchers will measure growth rates and height z-scores over the course of the year. Safety and any side effects will be closely observed throughout the study. The trial is sponsored by Ascendis Pharma AS and aims to provide detailed information about the effects of navepegritide in this adolescent population.

A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.